Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9373047 | 0.85 | MAPT (0.64) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL9373058 | 0.85 | MAPT (0.64) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL9373051 | 0.85 | MAPT (0.64) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL9973629 | 0.83 | CTRC (0.59) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL9369392 | 0.81 | MAPT (0.60) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL28876262 | 0.80 | KMT2A (0.70) | MAPTKDM4EL3MBTL1NPC1RAB9A | |
| SCHEMBL10308975 | 0.80 | KMT2A (0.74) | MAPTKDM4EL3MBTL1LMNAALDH1A1 | |
| SCHEMBL9975264 | 0.80 | L3MBTL1 (0.62) | MAPTL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL2988285 | 0.80 | L3MBTL1 (0.62) | MAPTL3MBTL1NPC1RAB9AALDH1A1 | |
| SCHEMBL2988282 | 0.80 | L3MBTL1 (0.62) | MAPTL3MBTL1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | MAPT 4100/4885KDM4E 2805/4885L3MBTL1 4646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.